Global Prevalence:
75 thousand
ALS is the most common
adult-onset motor neuron disease.
Global Prevalence:
24 million
AD is the most frequent cause of dementia.
Global Prevalence:
10 million
PD is the second most common age-related neurodegenerative disorder after AD
Charles is a Professor at Geisel School of Medicine & Director of the Center for Synthetic Immunity. He is a therapeutic T cell pioneer with 30+ issued patents, a first-in-class allogeneic CAR T cell approach, and innovations in multiple clinical trials.
Jake is Cofounder and CEO of Celdara Medical. He has 20 years in venture, corporate alliances, and biotech entrepreneurship. Under Jake’s leadership, Celdara returned a 68% 10 y IRR. Jake was an early mover in cell therapy through collaboration with Dr. Sentman.
David is a Senior Scientist at Geisel School of Medicine and the Center for Synthetic Immunity. He has investigated ALS for 18 years and cell therapy design and function for 5. David is an expert in immunology, neuroinflammation and experimental models of ALS.
Joana is Executive Director of R&D at Celdara Medical. She has extensive expertise in cell therapy, preclinical development and regulatory compliance after preclinical development.
Julie is a Program Lead at Celdara Medical. She has a PhD in neuroscience, 6 years in project management, and previous experience as a life science consultant at Putnam Associates.
